BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372-84. [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, Gupta S. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 33942566 DOI: 10.1002/cpdd.946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
5 Jia D, Dou Y, Li Z, Zhou X, Gao Y, Chen K, Cong W, Ma M, Wu Z, Li W. Design, synthesis and evaluation of a baicalin and berberine hybrid compound as therapeutic agent for ulcerative colitis. Bioorg Med Chem 2020;28:115697. [PMID: 33069077 DOI: 10.1016/j.bmc.2020.115697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mesonero F, Juliá B, Saldaña R, Savini C, Cañas M, Cea-Calvo L, Feo-Lucas L, Fernández S, Rodríguez-Lago I; ACCU, GETECCU and GETEII. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. Eur J Gastroenterol Hepatol 2021;33:501-7. [PMID: 32956185 DOI: 10.1097/MEG.0000000000001931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]